MedPath

Samsung Bioepis Co.,Ltd.

Samsung Bioepis Co.,Ltd. logo
🇩🇰Denmark
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

13

Active:2
Completed:4

Trial Phases

3 Phases

Phase 1:3
Phase 2:1
Phase 3:9

Drug Approvals

6

SFDA:6

Drug Approvals

Renflexis

Approval Date
Jul 18, 2025
Company
SAMSUNG BIOLOGICS CO., LTD.
SFDA

Ontruzant

Approval Date
Jul 18, 2025
Company
PATHEON ITALIA SPA
SFDA

Ontruzant

Approval Date
Jul 18, 2025
Company
FAREVA PAU
SFDA

HADLIMA 40MG/0.8ML INJECTION IN PFP

Approval Date
Jul 18, 2025
Company
Catalent Belgium SA
SFDA

Clinical Trials

Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials

Phase 3
9 (69.2%)
Phase 1
3 (23.1%)
Phase 2
1 (7.7%)
No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.